Johnson & Johnson Stock Price, News & Analysis

Johnson & Johnson (NYSE: JNJ) announced the presentation of 23 abstracts featuring new real-world and clinical trial data from its neuropsychiatry portfolio at Psych Congress. Key highlights include five-year safety data from 35,000 adults treated with SPRAVATO®, insights into anhedonia in major depressive disorder (MDD), and an analysis of over 30,000 adults with schizophrenia examining the link between symptom relapse and mortality risk. The presentations cover treatment-resistant depression, MDD, and schizophrenia, showcasing data on SPRAVATO®'s long-term safety and efficacy, as well as insights from the company's long-acting injectable portfolio.

A Bridgeport jury has awarded $15 million to Evan Plotkin and his wife Martha Barry-Plotkin in a verdict against Johnson & Johnson (NYSE:JNJ) and several subsidiaries for damage linked to asbestos in the company's talc-based Baby Powder. Mr. Plotkin, diagnosed with mesothelioma in 2021, was exposed to J&J's product through personal use beginning in the 1950s and his children's use through the 2000s.

The jury awarded $15 million in compensatory damages and affirmed that punitive damages were justified, potentially increasing the final verdict amount. J&J subsidiaries Kenvue, Holdco, Pecos River, LLT, and LTL were also defendants in the lawsuit. J&J withdrew its talc powder from North American sales in 2020.

Mr. Plotkin, an artist and father of three, is recognized for his transformative work in downtown Springfield, Mass., as founder of City Mosaic, a nonprofit dedicated to fostering the area's visual arts community.

Johnson & Johnson (NYSE: JNJ) announced positive results from the Phase 2/3 Vibrance-MG study of nipocalimab in anti-AChR positive adolescents (aged 12-17) with generalized myasthenia gravis (gMG). The study showed that nipocalimab plus standard of care achieved sustained disease control over 24 weeks, with a 70% reduction in IgG and improvements in MG-ADL and QMG scores. Notably, 4 out of 5 patients achieved minimum symptom expression.

Nipocalimab was well-tolerated with no serious adverse events or discontinuations. These results are consistent with findings from the pivotal study in adult gMG patients. Johnson & Johnson has submitted applications to the FDA and EMA for nipocalimab's approval in gMG treatment.

Johnson & Johnson (NYSE: JNJ) has announced its quarterly dividend for the fourth quarter of 2024. The company's Board of Directors has declared a cash dividend of $1.24 per share on its common stock. This dividend will be payable on December 10, 2024 to shareholders of record at the close of business on November 26, 2024. The ex-dividend date is also set for November 26, 2024.

Johnson & Johnson (NYSE: JNJ) reported Q3 2024 results with sales growth of 5.2% to $22.5 billion. Operational growth was 6.3% and adjusted operational growth was 5.4%. Earnings per share (EPS) decreased by 34.3% to $1.11 due to a one-time special charge and acquired IPR&D. Adjusted EPS decreased by 9.0% to $2.42.

The company highlighted significant pipeline progress, including approvals for TREMFYA and RYBREVANT, and the submission of an IDE for the OTTAVA robotic system. JNJ increased its full-year 2024 operational sales guidance but updated its adjusted operational EPS guidance to reflect the acquisition of V-Wave.

Innovative Medicine worldwide operational sales grew 6.3%, driven by products like DARZALEX and TREMFYA. MedTech worldwide operational sales grew 6.4%, with growth in cardiovascular, vision, and general surgery products.

Johnson & Johnson (NYSE: JNJ) announces its participation in the Stifel 2024 Healthcare Conference on Monday, November 18th, at the Lotte New York Palace in New York. Michael Bodner, Group President of Heart Recovery & Circulatory Restoration, will represent the company in a session scheduled for 10:55 a.m. (Eastern Time).

The event will feature a live audio webcast accessible to investors and interested parties through the Johnson & Johnson website at www.investor.jnj.com. An audio replay will be available approximately 48 hours after the webcast concludes.

Johnson & Johnson (NYSE: JNJ) announced impressive results for TREMFYA® (guselkumab) in treating Crohn's disease (CD) and ulcerative colitis (UC). Key findings include:

1. TREMFYA® showed superior endoscopic remission rates compared to ustekinumab in CD patients and placebo in UC patients, for both biologic-naïve and biologic-refractory groups.

2. In CD, 44-46.1% of biologic-naïve patients achieved endoscopic remission with TREMFYA® vs 29.8% with ustekinumab.

3. In UC, 38.1-41.7% of biologic-naïve patients achieved endoscopic remission with TREMFYA® vs 20.4% with placebo.

4. TREMFYA® is now FDA-approved for UC and under review for CD in the U.S. and Europe.

These results suggest TREMFYA® could offer a differentiated treatment option for CD and UC patients, including those new to biologics and those who have failed prior therapies.

Johnson & Johnson (NYSE: JNJ) has successfully completed the acquisition of V-Wave , a privately-held company specializing in innovative heart failure treatments. V-Wave will operate under Johnson & Johnson MedTech, strengthening the company's position in cardiovascular disease management. The acquisition brings V-Wave's Ventura® Interatrial Shunt, a novel minimally invasive device, into JNJ's portfolio.

This strategic move aims to address heart failure, a critical unmet medical need, and accelerates JNJ's expansion into high-growth markets. It complements JNJ's existing platforms for coronary and peripheral artery diseases, heart recovery, and atrial fibrillation. The transaction, accounted for as an asset acquisition, will result in an in-process research and development charge of approximately $600 million in Q4 2024 and is expected to dilute adjusted EPS by $0.24 in 2024 and $0.06 in 2025.

Johnson & Johnson (NYSE: JNJ) has announced its participation in the Guggenheim Global Healthcare Conference on Tuesday, November 12th, at the InterContinental Boston. Biljana Naumovic, President of Solid Tumor, U.S. Oncology, and Mark Wildgust, Vice President of Global Medical Affairs Oncology, will represent the company in a session scheduled for 10:30 a.m. (Eastern Time).

A live audio webcast of the session will be available to investors and interested parties on the Johnson & Johnson website at www.investor.jnj.com. An audio replay will be accessible approximately 48 hours after the webcast. This event provides an opportunity for stakeholders to gain insights into JNJ's oncology initiatives and healthcare strategies.